CVS Group Reports 5.9% Revenue Increase to £712.8m with Australian Expansion Now Over 11% of Total Income

Strong Revenue Growth and Operational Momentum Amid UK Market Challenges

For the fiscal year ending 30 June 2026, CVS Group achieved a 5.9% revenue increase to £712.8m, maintaining growth despite persistent UK consumer weakness. Like-for-like sales rose 2.1%, improving from 0.2% the previous year, highlighting operational strength even as companion animal practice footfall faces low consumer confidence. The company’s diversified UK and Australian presence helped mitigate regional economic headwinds.

This performance underscores CVS’s operational resilience, disciplined practice management, and strategic acquisition-driven expansion. The notable improvement in like-for-like sales confirms organic growth within existing practices despite broader macroeconomic challenges affecting pet owner spending. This solid growth trajectory reinforces investor confidence in CVS’s business model amid cyclical UK consumer pressures.

Australian Expansion Drives Earnings, Now 16% of EBITDA Contribution

CVS Group’s Australian segment has become a key earnings contributor, accounting for roughly 11% of group revenue but delivering about 16% of group EBITDA before central costs. During the year, the division expanded through six acquisitions comprising 14 practice sites and a minority interest buyout totaling A$91.0m / £45.6m, increasing the footprint from 29 to 35 practices covering 57 sites nationwide. Additionally, contracts were exchanged for two further South Australian acquisitions involving four sites valued at approximately A$9.3m / £4.6m, expected to complete shortly after the announcement.

The higher EBITDA contribution relative to revenue indicates superior margins in Australian operations, driven by efficient management or favorable market pricing. Management reports that these practices are outperforming business plans, with acquisition synergies enhancing results. The board remains confident in a robust acquisition pipeline in Australia, positioning the division as a vital medium-term growth engine and supporting accretive acquisition targets.

Adjusted EBITDA Matches Market Expectations with Stable Margins

CVS Group projects adjusted EBITDA of approximately £141.5m for the year ended 30 June 2026, precisely aligning with market consensus from ten analysts averaging £141.6m (range: £140.4m to £142.3m). This represents a £6.9m increase from £134.6m the prior year, reflecting 5.1% underlying earnings growth. Adjusted EBITDA excludes financing and exceptional items, offering a clear view of operational profitability.

The EBITDA margin held steady at 19.9%, compared to 20.0% previously, remaining within the 19% to 23% guidance. The slight 10 basis point compression reflects the integration of lower-margin acquisitions balanced by organic margin gains and operational leverage. This margin stability amid growth and acquisitions demonstrates effective integration and sustained profitability, a key metric for investors assessing CVS’s earnings conversion capability.

Disciplined Capital Expenditure Supporting Sustainable Growth and Returns

During the fiscal year, CVS invested £36.4m in capital expenditure, approximately 5.0% of revenue, focused on property, plant, equipment, and other projects. Management expects capital spending to normalize around £30m annually going forward, decreasing as a revenue percentage as the company matures and reduces new practice development intensity. This strategy reflects confidence in existing infrastructure supporting organic growth and customer retention, while allocating excess capital to shareholder returns and acquisitions.

The anticipated reduction in capital intensity enhances free cash flow and dividend potential. As capital expenditure declines to an expected 4.2% of revenue, more adjusted EBITDA will be available for debt repayment, dividends, and acquisitions. Management’s disciplined acquisition approach and willingness to temporarily exceed a 2.0x leverage ceiling for attractive deals underpin medium-term shareholder value creation.

Leverage Increase and Share Buyback Programme Enhance Shareholder Value

Net bank borrowings rose to £199.6m as of 30 June 2026, up from £160.2m at 31 December 2025 and £131.4m a year earlier, reflecting Australian acquisitions and the share buyback programme. The leverage ratio (net borrowings to annualized adjusted EBITDA) is estimated at 1.63x, compared to 1.41x and 1.18x at prior dates. The £50m buyback, launched on 26 May 2026, completed £11.7m during the year and is expected to continue until November 2026, moving leverage toward the 2.0x target.

This leverage increase is a strategic choice to return cash to shareholders while preserving acquisition capacity. CVS holds committed undrawn bank facilities of £132.0m and cash of £18.4m, ensuring financial flexibility. Management’s openness to temporarily exceed 2.0x leverage for attractive acquisitions reflects confidence in deal quality and cash flow strength, balancing capital structure prudence with strategic optionality.

Completion of CMA Process Brings Regulatory Certainty

CVS Group welcomed the Competition and Markets Authority’s final decision published on 24 March 2026, ending the regulatory review of the veterinary sector. The company confirmed compliance with most remedies and progress on others, including publishing price lists on practice websites in late 2025 and achieving joint branding across over 80% of UK companion animal practices, addressing transparency concerns.

The CMA process conclusion removes significant regulatory uncertainty impacting investor sentiment and strategic planning. Transparent pricing and branding initiatives align with CMA goals to improve consumer choice and competition. CVS’s proactive remedy implementation positions the company to operate confidently under the post-CMA framework without material enforcement risks, enabling focus on growth and acquisitions.

CEO Transition Underway with Focus on Governance and Continuity

Following Richard Fairman’s 30 March 2026 retirement announcement, the board is conducting a thorough search for his successor. Fairman remains committed to leading CVS until the new CEO is appointed, ensuring continuity and strategic execution. The board’s deliberate succession approach prioritizes candidate assessment quality over speed, reflecting strong governance and business stability.

While CEO transitions can introduce uncertainty, CVS mitigates risks through transparent communication and Fairman’s ongoing leadership. The new appointment will allow evaluation of potential strategic or capital allocation adjustments amid evolving market conditions. The process is expected to conclude before or shortly after the preliminary results on 24 September 2026, minimizing management uncertainty.

Veterinary Sector Fundamentals Support Medium-Term Growth Prospects

Operating in a sector with structurally favorable long-term trends, CVS benefits from rising pet ownership, increased per-household pet spending, and market consolidation. The group runs over 480 practices in the UK and Australia, supported by diagnostic laboratories serving both CVS and external clients, plus the Animed Direct online retail business. Employing 9,000 staff including 2,500 vets and 3,300 nurses, CVS maintains a skilled workforce underpinning quality and reputation.

The board’s reference to “structurally favourable dynamics” underscores confidence in enduring industry fundamentals despite short-term consumer weakness. Elevated pet ownership rates and a shift toward premium veterinary services support pricing power and margins. CVS’s diversified revenue streams—including primary care, referral hospitals, emergency services, diagnostics, and online retail—reduce reliance on any single area and provide multiple organic growth and margin expansion avenues as economic conditions improve.

Outlook and Upcoming Results Announcement

CVS acknowledges ongoing UK economic challenges and low consumer confidence affecting companion animal practice footfall, with these headwinds expected to persist near term. While no specific forward guidance was provided for FY ending 30 June 2027, the board expressed confidence in Australian expansion progress, CMA process completion, and strong sector fundamentals positioning the company for medium- to long-term shareholder value growth.

Investors should anticipate the full preliminary results on 24 September 2026 for detailed commentary on market outlook, acquisition pipeline, and capital allocation. The board’s cautious guidance likely reflects uncertainty over UK consumer spending and economic recovery timing. However, confidence in Australian momentum, regulatory clarity, and a robust balance sheet suggest continued earnings growth and shareholder returns despite cyclical pressures. An investor presentation on capital allocation and returns, accessible via webcast, demonstrates management’s commitment to transparent long-term strategy communication.